Artizan, a Yale University spinout focused on intestinal microbiota targets potentially responsible for inflammatory bowel disease, has been backed by investors including Brii Biosciences, bringing its total funding to $12m.

Artizan, a US-based inflammatory disease therapy spinout of Yale University targeting the intestinal microbiota, yesterday closed a series A round of undisclosed size that included medicines supplier Brii Biosciences. While Artizan did not confirm the size of the investment, it noted it had now obtained a total of $12m in funding. The spinout secured $5m…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.